BOTHELL, WA--(Marketwire - October 07, 2008) - MDRNA, Inc. (NASDAQ: MRNA) announced today that it has advanced its RNAi pipeline with the selection of a Lead Candidate in its hypercholesterolemia program targeting Apolipoprotein B (ApoB). The compound, designated MDR-04227, was developed using MDRNA's propriety drug discovery engine, which is built on a broad and enabling intellectual property estate and an in-house novel and proprietary delivery technology.
